1/11/2006 | BT | Protein Design maintained by Merrill at buy
|
1/9/2006 | BT | Protein Design Labs becomes PDL BioPharma
|
1/4/2006 | BT | Market Commentary: Kosan deal revival speculated; SGX range for IPO emerges; Depomed zooms; PDLI up 5%
|
11/18/2005 | CV | Market Commentary: Sonic, CompuCredit edge higher; Doral Financial surges amid rumors; Protein Design gains
|
11/18/2005 | BT | Market Commentary: Onyx gains after 'well-priced' deal; Elan, Biogen rise; Protein Design Labs up; Cubist higher
|
11/2/2005 | BT | JMP reiterates Protein Design at outperform
|
11/2/2005 | BT | Merrill maintains Protein Design at buy
|
11/1/2005 | BT | Roche, Protein Design Labs expand deal to develop daclizumab
|
11/1/2005 | CV | Market Commentary: Qwest, Chesapeake Energy to price $2 billion-plus in convertibles; new IPC paper trades actively
|
11/1/2005 | BT | Market Commentary: Cell Therapeutics prices $82 million notes to yield 6.75%; Nabi's stock dives on failed clinical trial
|
10/10/2005 | BT | Protein Design maintained by JMP at market outperform
|
10/10/2005 | BT | Merrill Lynch keeps Protein Design at buy
|
10/4/2005 | BT | Market Commentary: CancerVax crashes; Serono slips; Protein Design Labs cheered; Celgene off; Keryx up
|
10/3/2005 | BT | Amylin sales looking up as Biogen may face downside, Merrill report says
|
9/16/2005 | BT | Market Commentary: Meridian Biosciences slips in spot deal; Myogen, Geron deals show improved reception
|
9/16/2005 | BT | Protein Design Labs kept by Merrill at buy
|
9/14/2005 | PP | Market Commentary: China BAK Battery leads PIPEs with $43.45 million deal; gold offerings make a comeback
|
9/13/2005 | BT | Market Commentary: Immunomedics up; OSI rebounds; Celgene retreats; Protein Design Labs, Novavax, Cephalon all up
|
9/13/2005 | PP | Market Commentary: Protein Design Labs pockets $100 million from collaboration; mergers may generate more biotech PIPEs
|
9/13/2005 | BTPP | New Issue: Protein Design Labs raises $100 million in collaboration with Biogen
|
9/6/2005 | BT | Protein Design Labs kept by Merrill at buy
|
8/5/2005 | BT | Protein Design price target raised by Merrill
|
8/5/2005 | BT | Protein Design estimates raised by JMP Securities
|
8/3/2005 | BT | PDLI price target raised by JMP Securities
|
8/3/2005 | BT | Market Commentary: Lilly launches $1.5 billion floater; Human Genome $230 million convert at bat; MannKind taps PIPEs
|
8/3/2005 | CV | Market Commentary: Human Genome to price $230 million of convertibles; Reebok paper jumps on buyout news
|
8/3/2005 | BT | PDLI price target raised by Merrill Lynch
|
7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
3/14/2005 | CV | Market Commentary: JetBlue a laggard as airline paper up; Delta bankruptcy fears weigh; PDLI gains; Aquila up; Xoma off
|
2/16/2005 | CV | Market Commentary: Sybase issue climbs out of gate; BlackRock ends in gray market with no bid; Allied Waste slips
|
2/10/2005 | CV | Market Commentary: Guitar holders like acquisition; Coltec up; Protein Design seen re-priced, trades light at 98
|
2/9/2005 | CV | New Issue: Protein Design Labs sells $250 million of convertibles to yield 2.0%, up 30%
|
2/9/2005 | CV | Market Commentary: Protein Design Labs sweetened, sinks; Huntsman hotly pursued; Allergan, Sepracor off, Saks up
|
2/8/2005 | CV | Market Commentary: Southern Union advances, prices tight; Protein Design Labs seen rich; Level 3, EDS dive on results
|
2/7/2005 | CV | Protein Design Labs $250 million convertible talked at 1.25%-1.75% coupon, up 30%-35%
|
2/7/2005 | CV | Market Commentary: Southern Union, Protein Design launch; Pinnacle Airlines edges up, raises Northwest paper
|
8/16/2004 | CV | Market Commentary: LifePoint, Province up on merger, lift takeover risk; American Tower deal seen repriced; Aquila emerges
|
7/9/2004 | CV | Market Commentary: Nextel converts gain as stock sold short; Arch Coal buried by warning, Massey down, too
|
5/19/2004 | CV | Market Commentary: Calpine up after big drop last week; Kroll bonds flag while stock soars on merger news
|
5/17/2004 | CV | Market Commentary: Protein Design Labs plunges, Millennium set to rise on drug results; Thoratec, Tower deals emerge
|
9/29/2003 | CV | Protein Design Labs to redeem 51/2% convertibles
|
7/10/2003 | CV | S&P rates new Protein Design Labs convert CCC
|
7/9/2003 | CV | New Issue: Protein Design Labs sells $250 million convertible to yield 2.75%, up 33%
|
7/9/2003 | CV | Market Commentary: CMS deal revived with wider yield talk, joining TXU after close as power issues heat up
|
7/8/2003 | CV | Protein Design Labs $250 million convertibles yield 2.75%, up 33%
|
7/8/2003 | CV | Market Commentary: Traders note more summer-like flow; some profit taking seen as new deal party rocks on
|
7/7/2003 | CV | Market Commentary: HealthSouth converts bid up some 20 points on financials; trading sees post-holiday lull
|
7/7/2003 | CV | Protein Design Labs $200 million convertibles talked to yield 2.75-3.25%, up 30-35%
|
12/10/2002 | CV | Fitch rates Baxter mandatory A
|
7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
5/9/2002 | CV | Wachovia analyst sees PDLI convert as interesting high yield play
|
4/10/2002 | CV | Market Commentary: Duane Reade brings new deal in new structure; Biotechs, drugs higher on short covering
|
3/26/2002 | CV | Salomon analyst likes PDLI
|
3/21/2002 | CV | Convertibles gain as buyers emerge, PDLI clips slide
|
3/20/2002 | CV | Market Commentary: Convertibles drop; PDLI joins ViroPharma, other biotechs in freefall
|
2/28/2002 | CV | Market Commentary: Convertibles choppy, lower but GM deal upped to $3.25 billion
|
12/7/2001 | CV | Market Commentary: Convertible market slides as stock enthusiasm withers, no new deals
|